Table 2 |
|||
|
IL-1F8 protein levels in mouse and human joint samples and in mouse skin |
|||
|
Samples |
Patients/animals |
IL-1F8 (pg/mg protein) |
IL-1β (pg/mg protein) |
|
|
|||
|
Human synovium |
OA (n = 4) |
3.7 ± 1.4 |
3.6 ± 0.3 |
|
Inflammatory arthritis (n = 5) |
3.9 ± 1.0 |
11.6 ± 5.7a |
|
|
Mouse joint |
Naïve (n = 1) |
2.8 |
2.3 |
|
Nonarthritic (n = 1) |
2.7 |
4.5 |
|
|
CIA earlyb (n = 3) |
2.2 ± 0.3 |
16.6 ± 1.2c |
|
|
CIA lateb (n = 3) |
4.5 ± 1.4 |
8.8 ± 0.8 |
|
|
Mouse skin |
Control (n = 3) |
761.7 ± 313.4 |
16 ± 3 |
|
PMA (n = 3) |
14569.1 ± 3632.5d |
28 ± 3d |
|
|
|
|||
|
IL-1F8 protein levels were determined using enzyme-linked immunosorbent assay. aP < 0.05 versus osteoparthritis (OA), as assessed using the Mann-Whitney test. bCollagen-induced arthritis (CIA) early: days 1–7 after the onset of arthritis; CIA late: days 8–21 after onset of arthritis. cP < 0.05 versus late CIA, as assessed using analysis of variance. dP < 0.05 versus control, as assessed using analysis of variance. |
|||
|
Magne et al. Arthritis Research & Therapy 2006 8:R80 doi:10.1186/ar1946 |
|||